Lucid Diagnostics Inc.

AI Score

XX

Unlock

1.50
-0.02 (-1.32%)
At close: Mar 24, 2025, 3:59 PM
1.51
0.67%
After-hours: Mar 24, 2025, 05:56 PM EDT

Company Description

Lucid Diagnostics Inc. operates as a commercial-stage medical diagnostics technology company.

The company focuses on patients with gastroesophageal reflux disease, which is also known as chronic heartburn, acid reflux, or simply reflux, who are at risk of developing esophageal precancer and cancer, specifically highly lethal esophageal adenocarcinoma.

Its lead products include EsoGuard, a laboratory developed esophageal DNA test; and EsoCheck, an esophageal cell collection device.

The company was incorporated in 2018 and is based in New York, New York.

Lucid Diagnostics Inc. is a subsidiary of PAVmed Inc.

Lucid Diagnostics Inc.
Lucid Diagnostics Inc. logo
Country United States
IPO Date Oct 14, 2021
Industry Medical - Devices
Sector Healthcare
Employees 70
CEO Dr. Lishan Aklog M.D.

Contact Details

Address:
One Grand Central Place
New York, New York
United States
Website https://www.luciddx.com

Stock Details

Ticker Symbol LUCD
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001799011
CUSIP Number 54948X109
ISIN Number US54948X1090
Employer ID 82-5488042
SIC Code 3841

Key Executives

Name Position
Dr. Lishan Aklog M.D. Chairman & Chief Executive Officer
Dennis M. McGrath CPA Chief Financial Officer
Shaun M. O'Neill M.B.A. President & Chief Operating Officer
Dr. Amitabh Chak M.D. Co-Founder & Strategic Advisor
Dr. Brian J. deGuzman M.D. Chief Technology & Compliance Officer
Dr. Joseph Willis M.D. Co-founder & Strategic Advisor
Dr. Sanford D. Markowitz M.D., Ph.D. Co-Founder & Strategic Advisor
Dr. Suman M. Verma M.D., Ph.D. Chief Scientific Officer
Helen Moinova Ph.D. Co-Founder & Strategic Advisor
Michael Adam Gordon General Counsel & Secretary

Latest SEC Filings

Date Type Title
Mar 05, 2025 8-K Current Report
Mar 05, 2025 424B5 Filing
Mar 04, 2025 8-K Current Report
Mar 04, 2025 8-K Current Report
Feb 25, 2025 8-K Current Report
Feb 21, 2025 4 Filing
Feb 21, 2025 4 Filing
Feb 21, 2025 4 Filing
Feb 21, 2025 4 Filing
Feb 21, 2025 4 Filing